Ruxolitinib Reaches 55% Response Rate in Pivotal GVHD Trial
Ruxolitinib combined with corticosteroids induced an overall response rate of 55% at day 28 in patients with steroid-refractory acute graft-versus-host disease, meeting the primary endpoint of the phase II REACH1 trial.
Source: OncLive